Bosh sahifaSGEN • BMV
add
Seagen
Yopilish kursi
3 711,48 $
Yillik diapazon
3 711,48 $ - 3 711,48 $
Bozor kapitalizatsiyasi
43,15 mlrd USD
Narx/foyda
-
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | sen, 2023info | Y/Y qiyosi |
---|---|---|
Daromad | 648,65 mln | 27,11% |
Joriy xarajat | 262,69 mln | 24,86% |
Sof foyda | -215,79 mln | -13,09% |
Sof foyda marjasi | -33,27 | 11,02% |
Har bir ulushga tushum | -1,15 | -11,65% |
EBITDA | -209,33 mln | -19,47% |
Amaldagi soliq stavkasi | 0,26% | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | sen, 2023info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 1,24 mlrd | -29,86% |
Jami aktivlari | 3,63 mlrd | 0,42% |
Jami passivlari | 1,08 mlrd | 35,94% |
Umumiy kapital | 2,55 mlrd | — |
Tarqatilgan aksiyalar | 188,66 mln | — |
Narxi/balansdagi bahosi | 274,52 | — |
Aktivlardan daromad | -16,01% | — |
Kapitaldan daromad | -21,12% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | sen, 2023info | Y/Y qiyosi |
---|---|---|
Sof foyda | -215,79 mln | -13,09% |
Operatsiyalardan naqd pul | -35,82 mln | 58,21% |
Sarmoyadan naqd pul | 142,49 mln | 119,31% |
Moliyadan naqd pul | 15,52 mln | -15,59% |
Naqd pulning sof oʻzgarishi | 119,90 mln | 1 958,05% |
Boʻsh pul | 71,52 mln | 1 141,10% |
Haqida
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Tashkil etilgan
15-iyl, 1997
Sayt
Xodimlar soni
3 256